Grail (GRAL) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $135.46, -3.04% vs the prior close of $139.70.
- Volume 701.30K shares, 0.6x its 50-day average.
- New SEC filings: 144 (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
GRAL slides 3.0% to $135.46. Closed at $135.46, -3.04% vs the prior close of $139.70. Day range $132.09–$139.50, opened at $136.00.
GRAL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — GRAL slides 3.0% to $135.46
- Closed at $135.46, -3.04% vs the prior close of $139.70. Day range $132.09–$139.50, opened at $136.00.
- Volume was 701.30K shares, 0.6x its 50-day average of 1.09M.
- Price is +39.0% vs its 50-day average ($97.45) and +78.5% vs its 200-day average ($75.89).
- 52-week range $41.50–$166.48; today's close sits at 75% of that range, 18.6% below the 52-week high.
Oct 14, 2026 — GRAL dips 0.5% to $139.70
- Closed at $139.70, -0.46% vs the prior close of $140.35. Day range $138.00–$144.18, opened at $139.79.
- Volume was 826.10K shares, 0.8x its 50-day average of 1.08M.
- Price is +45.2% vs its 50-day average ($96.23) and +84.7% vs its 200-day average ($75.65).
- 52-week range $41.50–$166.48; today's close sits at 79% of that range, 16.1% below the 52-week high.
Oct 13, 2026 — GRAL rises 2.2% to $140.35
- Closed at $140.35, +2.17% vs the prior close of $137.37. Day range $135.24–$142.17, opened at $138.09.
- Volume was 702.90K shares, 0.7x its 50-day average of 1.08M.
- Price is +47.9% vs its 50-day average ($94.89) and +86.1% vs its 200-day average ($75.41).
- 52-week range $41.50–$166.48; today's close sits at 79% of that range, 15.7% below the 52-week high.
Oct 12, 2026 — GRAL dips 2.3% to $137.37
- Closed at $137.37, -2.28% vs the prior close of $140.58. Day range $133.86–$140.49, opened at $137.41.
- Volume was 650.90K shares, 0.6x its 50-day average of 1.08M.
- Price is +46.9% vs its 50-day average ($93.49) and +82.7% vs its 200-day average ($75.17).
- 52-week range $41.50–$166.48; today's close sits at 77% of that range, 17.5% below the 52-week high.
Oct 9, 2026 — GRAL jumps 6.0% to $140.58
- Closed at $140.58, +6.01% vs the prior close of $132.61. Day range $133.31–$142.57, opened at $133.50.
- Volume was 773.70K shares, 0.7x its 50-day average of 1.07M.
- Price is +52.6% vs its 50-day average ($92.11) and +87.6% vs its 200-day average ($74.94).
- 52-week range $41.50–$166.48; today's close sits at 79% of that range, 15.6% below the 52-week high.
Oct 8, 2026 — GRAL ends flat (-0.2%) to $132.61, 3 down days in a row
- Closed at $132.61, -0.22% vs the prior close of $132.90. Day range $127.46–$134.55, opened at $130.00.
- Volume was 1.31M shares, 1.2x its 50-day average of 1.06M.
- Price is +46.2% vs its 50-day average ($90.72) and +77.5% vs its 200-day average ($74.71).
- 52-week range $41.50–$166.48; today's close sits at 73% of that range, 20.3% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — GRAL slides 3.2% to $132.90
- Closed at $132.90, -3.19% vs the prior close of $137.28. Day range $130.56–$139.00, opened at $134.00.
- Volume was 992.50K shares, 0.9x its 50-day average of 1.05M.
- Price is +48.8% vs its 50-day average ($89.34) and +78.4% vs its 200-day average ($74.50).
- 52-week range $41.50–$166.48; today's close sits at 73% of that range, 20.2% below the 52-week high.
Oct 6, 2026 — GRAL slides 10.9% to $137.28 on 2.0x normal volume
- Closed at $137.28, -10.90% vs the prior close of $154.08. Day range $135.80–$166.48, opened at $159.43.
- Volume was 2.04M shares, 2.0x its 50-day average of 1.02M — unusually heavy trading.
- Price is +56.1% vs its 50-day average ($87.97) and +84.8% vs its 200-day average ($74.28).
- 52-week range $41.50–$166.48; today's close sits at 77% of that range, 17.5% below the 52-week high.
Oct 5, 2026 — GRAL jumps 7.6% to $154.08, a 52-week high
- Closed at $154.08, +7.55% vs the prior close of $143.26. Day range $140.30–$156.49, opened at $143.00.
- Volume was 1.47M shares, 1.5x its 50-day average of 996.90K.
- Price is +78.0% vs its 50-day average ($86.56) and +108.2% vs its 200-day average ($74.02).
- 52-week range $41.50–$156.49; today's close sits at 98% of that range, 1.5% below the 52-week high.
Oct 2, 2026 — GRAL jumps 8.1% to $143.26, a 52-week high
- Closed at $143.26, +8.07% vs the prior close of $132.56. Day range $134.45–$143.50, opened at $135.52.
- Volume was 873.80K shares, 0.9x its 50-day average of 992.37K.
- Price is +68.9% vs its 50-day average ($84.83) and +94.4% vs its 200-day average ($73.68).
- 52-week range $41.50–$151.46; today's close sits at 93% of that range, 5.4% below the 52-week high.
GRAL latest news & SEC filings
Every SEC filing by or about GRAL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 7, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Partridge Andrew John sold 7,873 shares at $146.39 (≈$1.15M) on Oct 5, 2026; now holds 155,865
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Freidin Aaron sold 23,619 shares at $146.39 (≈$3.46M) on Oct 5, 2026; now holds 225,364
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 5, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 23, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Freidin Aaron sold 1,779 shares at $92.26 (≈$164.14K) on Sep 21, 2026; now holds 251,304
- Freidin Aaron sold 1,800 shares at $93.92 (≈$169.05K) on Sep 21, 2026; now holds 249,504
- Freidin Aaron sold 521 shares at $95.00 (≈$49.49K) on Sep 21, 2026; now holds 248,983
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $44.69M (prior year $35.54M) (+25.7% vs Jun 30, 2025)
- Net income: -$110.25M (prior year -$113.98M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$2.56 (prior year -$3.18) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 28, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 22, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade GRAL
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 19, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.57% (largest 33.7%). That is a volatile stock.
- Liquidity: about 1.50M shares (≈$202.53M) trade per day on average.
- 52-week position: $135.46 vs a range of $41.50–$166.48 (75% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Aaron Freidin sold 1,779 shares on Sep 21, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 5, 2026; 8-K Jun 22, 2026.
- Share count: 44.67M shares outstanding (Aug 3, 2026), +23.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Services-Medical Laboratories.
GRAL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 136.00 | 139.50 | 132.09 | 135.46 | 701.30K |
| Oct 14, 2026 | 139.79 | 144.18 | 138.00 | 139.70 | 826.10K |
| Oct 13, 2026 | 138.09 | 142.17 | 135.24 | 140.35 | 702.90K |
| Oct 12, 2026 | 137.41 | 140.49 | 133.86 | 137.37 | 650.90K |
| Oct 9, 2026 | 133.50 | 142.57 | 133.31 | 140.58 | 773.70K |
| Oct 8, 2026 | 130.00 | 134.55 | 127.46 | 132.61 | 1.31M |
| Oct 7, 2026 | 134.00 | 139.00 | 130.56 | 132.90 | 992.50K |
| Oct 6, 2026 | 159.43 | 166.48 | 135.80 | 137.28 | 2.04M |
| Oct 5, 2026 | 143.00 | 156.49 | 140.30 | 154.08 | 1.47M |
| Oct 2, 2026 | 135.52 | 143.50 | 134.45 | 143.26 | 873.80K |
| Oct 1, 2026 | 138.23 | 141.54 | 132.04 | 132.56 | 1.09M |
| Sep 30, 2026 | 138.27 | 151.46 | 136.00 | 140.12 | 1.92M |
| Sep 29, 2026 | 132.75 | 140.88 | 131.20 | 136.57 | 920.60K |
| Sep 28, 2026 | 128.90 | 134.42 | 126.74 | 132.63 | 1.11M |
| Sep 25, 2026 | 123.50 | 127.67 | 118.45 | 126.89 | 1.29M |
| Sep 24, 2026 | 105.50 | 126.81 | 101.98 | 125.21 | 3.44M |
| Sep 23, 2026 | 108.52 | 108.52 | 108.52 | 108.52 | 0 |
| Sep 22, 2026 | 106.75 | 112.58 | 104.00 | 108.52 | 3.26M |
| Sep 21, 2026 | 93.74 | 111.50 | 92.00 | 107.97 | 3.52M |
| Sep 18, 2026 | 81.48 | 82.85 | 78.20 | 80.77 | 3.00M |
About Grail
Grail (GRAL) is listed on the Nasdaq and classified by the SEC under “Services-Medical Laboratories”. Its business address is in SUNNYVALE, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1699031.
GRAL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| William J Chase | Director | Jul 16, 2026 |
| Sarah Krevans | Director | Jun 22, 2026 |
| Steven Mizell | Director | Jul 16, 2026 |
| Joshua J. Ofman | Chief Executive Officer | Sep 23, 2026 |
| Robert P Ragusa | Chief Executive Officer | Apr 9, 2026 |
| Gregory L Summe | Director | Jul 16, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Aaron Freidin | Chief Financial Officer | Sep 23, 2026 |
| Joshua J. Ofman | Chief Executive Officer | Sep 23, 2026 |
| Andrew John Partridge | Chief Growth Officer | Jun 5, 2026 |
| Robert P Ragusa | Chief Executive Officer | Apr 9, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 21, 2026 | Aaron Freidin | Sale | 1,779 | $92.26 |
| Sep 21, 2026 | Aaron Freidin | Sale | 521 | $95.00 |
| Sep 21, 2026 | Aaron Freidin | Sale | 1,800 | $93.92 |
| Sep 21, 2026 | Joshua J. Ofman | Sale | 1,400 | $97.84 |
| Sep 21, 2026 | Joshua J. Ofman | Sale | 421 | $99.85 |
| Sep 21, 2026 | Joshua J. Ofman | Sale | 2,100 | $100.68 |
| Sep 21, 2026 | Joshua J. Ofman | Sale | 10,000 | $110.00 |
| Sep 21, 2026 | Joshua J. Ofman | Sale | 6,200 | $96.43 |
| Sep 21, 2026 | Joshua J. Ofman | Sale | 1,454 | $93.61 |
| Sep 21, 2026 | Joshua J. Ofman | Sale | 2,125 | $92.32 |
| Sep 21, 2026 | Joshua J. Ofman | Sale | 37,752 | $94.98 |
| Aug 27, 2026 | Joshua J. Ofman | Sale | 5,000 | $85.02 |
| Aug 27, 2026 | Aaron Freidin | Sale | 7,900 | $85.01 |
| Jun 4, 2026 | Andrew John Partridge | Sale | 1,491 | $61.08 |
| Apr 8, 2026 | Aaron Freidin | Sale | 45,806 | $49.92 |
GRAL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $147.17M | $-408.35M | -11.11 | $-299.01M |
| Dec 31, 2024 | $125.59M | $-2.03B | -63.54 | $-577.16M |
| Dec 31, 2023 | $93.11M | $-1.47B | -47.21 | $-595.80M |
| Jan 1, 2023 | $55.55M | $-5.40B | -173.89 | $-561.31M |
Latest balance sheet: total assets $2.84B, total liabilities $301.03M, cash $55.65M (as of Jun 30, 2026).
GRAL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $74.18 |
| May 5, 2026 | 8-K Item 2.02 (results) | $54.40 |
| Feb 19, 2026 | 8-K Item 2.02 (results) | $101.53 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $105.93 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $84.77 |
| Oct 16, 2025 | 8-K Item 2.02 (results) | $86.41 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $33.60 |
| May 13, 2025 | 8-K Item 2.02 (results) | $42.89 |
| Feb 20, 2025 | 8-K Item 2.02 (results) | $47.76 |
| Jan 15, 2025 | 8-K Item 2.02 (results) | $17.58 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $15.09 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Services-Medical Laboratories
Natera (NTRA)Quest Diagnostics (DGX)Guardant Health (GH)Labcorp (LH)Celcuity (CELC)Caris Life Sciences (CAI)CareDx (CDNA)Fortrea (FTRE)Veracyte (VCYT)BillionToOne (BLLN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on GRAL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.